28 Results for "

Ulcerative Colitis Model

" in MedChemExpress (MCE) Product Catalog:
Products (28)

28 Results for "Ulcerative Colitis Model" in MCE Product Catalog:

Cat. No.: HY-173129
Research Areas:  

Inflammation/Immunology

Anti-inflammatory agent 97 (Compound 1l), an anti-inflammation agent, can also inhibit oxidative stress. Anti-inflammatory agent 97 can inhibit the colonic shortening and suppress inflammatory symptoms of the colonic tissue in the DSS (HY-116282C)-induced ulcerative colitis mice model. Anti-inflammatory agent 97 can regulate the inflammation-related TLR4/NF-κB signaling pathway and the oxidative stress-related Nrf2/HO-1 signaling pathway .
loading...
    loading...
Cat. No.: HY-162641
Research Areas:  

Inflammation/Immunology

AF-45 inhibits IRAK4 and IRAK1, with IC50s of 128 nM and 1765 nM. AF-45 inhibits the release of IL-6 and TNF-α in macrophages, with IC50s of 0.53-1.54 μM and 0.6-2.75 μM. AF-45 is also an inhibitor for NF-κB/MAPK signaling pathway. AF-45 exhibits anti-inflammatory activities against DSS-induced ulcerative colitis and Lipopolysaccharide (HY-D1056)-induced acute lung injury in mouse model. AF-45 exhibits good pharmacokinetic characteristics in rat models .
loading...
    loading...
Cat. No.: HY-183370
Research Areas:  

Inflammation/Immunology

JAK2/STAT3-IN-2 is an orally active JAK2/STAT3 inhibitor. JAK2/STAT3-IN-2 inhibits the phosphorylation of tyrosine residues in JAK2 and STAT3, blocks downstream signal transduction, disrupts the dimerization and nuclear translocation of STAT3, and suppresses pro-inflammatory transcriptional activity. JAK2/STAT3-IN-2 inhibits the expression of IL-17A and IL-17F, reduces immune cell infiltration, and inhibits the production of NO simultaneously. JAK2/STAT3-IN-2 exerts a protective effect in a mouse model of ulcerative colitis induced by DSS (HY-116282C). JAK2/STAT3-IN-2 can be used for the research of ulcerative colitis .
loading...
    loading...
Cat. No.: HY-184327
Research Areas:  

Inflammation/Immunology

Anti-inflammatory agent 117 is an orally active anti-inflammatory agent and c-Kit kinase inhibitor with an IC50 of 15.2 μM. Anti-inflammatory agent 117 blocks the NF-κB signaling pathway and inhibits the release of IL-6. Anti-inflammatory agent 117 exhibits anti-inflammatory effects in mouse models of acute lung injury, sepsis and ulcerative colitis. Anti-inflammatory agent 117 can be used in research related to acute lung injury, sepsis and ulcerative colitis .
loading...
    loading...
Cat. No.: HY-D3234
CAS No.: 2409037-97-2
Cy-AP is a hypoxia-sensitive near-infrared Fluorescent probe (emission wavelength: 725 nm). Cy-AP exhibits no fluorescence under normoxic microenvironments, while under hypoxic microenvironments, its azo group is reduced, releasing strong near-infrared fluorescence with an emission at 725 nm. Cy-AP enables visualization of intracellular hypoxic status through multiple imaging modalities .
loading...
    loading...
Cat. No.: HY-174990A
CAS No.: 2927452-82-0
Target:  

Drug Isomer 15-PGDH

Research Areas:  

Inflammation/Immunology

HW201877 enantiomer is the enantiomer of HW201877 (HY-174990) and is 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor with an IC50 of 12.2 nM. HW201877 enantiomer can be used for the research of inflammatory bowel disease, idiopathic pulmonary fibrosis, ulcerative colitis, and Crohn's disease .
loading...
    loading...
Cat. No.: HY-179379
Target:  

Drug Derivative

Research Areas:  

Inflammation/Immunology

EP4 receptor agonist 3 prodrug (Compound 9) is a prodrug of EP4 receptor agonist (Compound 1a). EP4 receptor agonist 3 prodrug itself has no agonistic activity on the EP4 receptor and needs to be specifically hydrolyzed by intestinal alkaline phosphatase (IAP) in the intestine to release the active molecule, which then exerts the EP4 receptor agonistic effect locally in the intestine. EP4 receptor agonist 3 prodrug has colonic targeting properties and significantly alleviates colitis in mice .
loading...
    loading...
Cat. No.: HY-187103
CAS No.: 2241039-80-3
Target:  

JAK

Research Areas:  

Inflammation/Immunology

JAK1-IN-22 is a JAK1-selective inhibitor with an IC50 of 1.84 μM. JAK1-IN-22 exerts no significant inhibitory effect on JAK2 and JAK3. JAK1-IN-22 can be used in the research of JAK1-related diseases such as asthma, alopecia areata, and type 1 diabetes .
loading...
    loading...